Publication: 4696

Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index
      QxMD      Google Scholar   
Citation:
JAMA Netw Open vol 8 (11) e2540931
Year:
2025
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub-ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Book Volume:
Parents:
4622  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
Pfizer; Private donors: Ipsen, DebioPharm, TerSera, AstraZeneca  
Grants:
U10CA180821; SWOG U10CA180888, UG1CA233160, UG1CA233329; ECOG-ACRIN U10CACA180820, U10CA180794; NRG Oncology U10CA180868, U10CA180822, UG1CA189867; Canadian Cancer Trials Group U10CA180863, 707213; NHMRC grant numbers 351161, 510788, 1105058; CA075362; KG080081; Breast Cancer Research Foundation (16-185, 17-187, 18-003, 19-011, 20-011, 21-011  
Corr. Author:
 
Authors:
                                                                   
Networks:
11076, LAPS-IL057, LAPS-MN026, LAPS-PA015, NY018, NY167, OH070   
Study
IBCSG-24-02 (SOFT-TEXT)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: